

**Clinical trial results:****A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium difficile toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium difficile toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium difficile toxin A and toxin B) in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection (MODIFY I)**

Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.

**Summary**

EudraCT number	2011-004590-90
Trial protocol	DE ES CZ BE DK PT AT IT GB
Global end of trial date	09 December 2014

**Results information**

Result version number	v1 (current)
This version publication date	06 February 2016
First version publication date	06 February 2016

**Trial information****Trial identification**

Sponsor protocol code	3415A-001
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01241552
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 December 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 December 2014
Global end of trial reached?	Yes
Global end of trial date	09 December 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Primary Objective #1 (at interim analysis) and #2 (at final analysis): To determine if treatment with a single infusion of combined monoclonal antibody therapy (MK-3415A) with standard of care therapy decreases the proportion of participants with CDI recurrence over a period of 12 weeks as compared to treatment with a single infusion of individual monoclonal antibody therapy (MK-3415 or MK-6072) with standard of care therapy.

Primary Objective #3: To determine if treatment with a single infusion of monoclonal antibody therapy with standard of care therapy (combined monoclonal antibody therapy [MK-3415A] and possibly the separate individual monoclonal antibody therapy [MK-3415 and/or MK-6072]) decreases the proportion of participants with CDI recurrence over a period of 12 weeks as compared to treatment with a single infusion of placebo with standard of care therapy.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy:

Oral SOC antibiotic therapy (metronidazole, vancomycin, or fidaxomicin) for a primary or recurrent episode of CDI.

Evidence for comparator: -

Actual start date of recruitment	10 October 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 52
Country: Number of subjects enrolled	Austria: 18
Country: Number of subjects enrolled	Belgium: 28
Country: Number of subjects enrolled	Brazil: 11
Country: Number of subjects enrolled	Canada: 89
Country: Number of subjects enrolled	Chile: 55
Country: Number of subjects enrolled	Colombia: 23
Country: Number of subjects enrolled	Czech Republic: 34
Country: Number of subjects enrolled	Denmark: 69

Country: Number of subjects enrolled	Germany: 31
Country: Number of subjects enrolled	Israel: 85
Country: Number of subjects enrolled	Italy: 82
Country: Number of subjects enrolled	Mexico: 8
Country: Number of subjects enrolled	New Zealand: 22
Country: Number of subjects enrolled	Portugal: 25
Country: Number of subjects enrolled	South Africa: 10
Country: Number of subjects enrolled	Spain: 85
Country: Number of subjects enrolled	United Kingdom: 37
Country: Number of subjects enrolled	United States: 688
Worldwide total number of subjects	1452
EEA total number of subjects	409

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	721
From 65 to 84 years	581
85 years and over	150

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants 18 years of age or older, with a diagnosis of CDI were enrolled in this trial.

### Period 1

Period 1 title	Treatment Period 1 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	MK-3415 + SOC

Arm description:

Single intravenous (IV) infusion of 10 mg/kg MK-3415  
+ SOC for CDI

Arm type	Experimental
Investigational medicinal product name	MK-3415
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)

Investigational medicinal product name	SOC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOC for CDI was antibiotic therapy consisting of metronidazole, vancomycin, or fidaxomicin prescribed for 10 to 14 days beginning prior to or on the day of study drug

<b>Arm title</b>	MK-6072+ SOC
------------------	--------------

Arm description:

Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI

Arm type	Experimental
Investigational medicinal product name	MK-6072
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

A single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

Investigational medicinal product name	SOC
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOC for CDI was antibiotic therapy consisting of metronidazole, vancomycin, or fidaxomicin prescribed for 10 to 14 days beginning prior to or on the day of study drug

<b>Arm title</b>	MK-3415A + SOC
------------------	----------------

Arm description:

Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI

Arm type	Experimental
Investigational medicinal product name	SOC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOC for CDI was antibiotic therapy consisting of metronidazole, vancomycin, or fidaxomicin prescribed for 10 to 14 days beginning prior to or on the day of study drug

Investigational medicinal product name	MK-3415A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

A single IV infusion of MK3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

<b>Arm title</b>	Placebo Comparator + SOC
------------------	--------------------------

Arm description:

Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

A single IV infusion of normal saline (0.9% sodium chloride)

Investigational medicinal product name	SOC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOC for CDI was antibiotic therapy consisting of metronidazole, vancomycin, or fidaxomicin prescribed for 10 to 14 days beginning prior to or on the day of study drug

<b>Number of subjects in period 1</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC
Started	242	403	403
Treated	235	392	388
Completed	201	340	343
Not completed	41	63	60
Consent withdrawn by subject	7	15	14
Physician decision	2	4	2
Adverse event, non-fatal	1	1	-
Death	26	30	20
Technical Problems	2	-	2
Progressive Disease	-	-	1
Lost to follow-up	2	11	15
Lack of efficacy	1	-	-
Protocol deviation	-	2	6

<b>Number of subjects in period 1</b>	Placebo Comparator + SOC
Started	404
Treated	397
Completed	340
Not completed	64
Consent withdrawn by subject	15
Physician decision	3
Adverse event, non-fatal	-
Death	25
Technical Problems	2
Progressive Disease	2
Lost to follow-up	16
Lack of efficacy	-
Protocol deviation	1

## Baseline characteristics

### Reporting groups

Reporting group title	MK-3415 + SOC
Reporting group description:	
Single intravenous (IV) infusion of 10 mg/kg MK-3415 + SOC for CDI	
Reporting group title	MK-6072+ SOC
Reporting group description:	
Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI	
Reporting group title	MK-3415A + SOC
Reporting group description:	
Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI	
Reporting group title	Placebo Comparator + SOC
Reporting group description:	
Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI	

Reporting group values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC
Number of subjects	242	403	403
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	117	210	195
From 65-84 years	92	153	178
85 years and over	33	40	30
Age Continuous			
Units: years			
arithmetic mean	64.2	61.1	62.5
standard deviation	± 16.8	± 18.5	± 17.8
Gender Categorical			
Units: Subjects			
Female	137	238	224
Male	105	165	179

Reporting group values	Placebo Comparator + SOC	Total	
Number of subjects	404	1452	
Age Categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	

Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	199	721	
From 65-84 years	158	581	
85 years and over	47	150	
Age Continuous			
Units: years			
arithmetic mean	62.9		
standard deviation	± 18.3	-	
Gender Categorical			
Units: Subjects			
Female	230	829	
Male	174	623	

## End points

### End points reporting groups

Reporting group title	MK-3415 + SOC
Reporting group description:	
Single intravenous (IV) infusion of 10 mg/kg MK-3415 + SOC for CDI	
Reporting group title	MK-6072+ SOC
Reporting group description:	
Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI	
Reporting group title	MK-3415A + SOC
Reporting group description:	
Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI	
Reporting group title	Placebo Comparator + SOC
Reporting group description:	
Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI	

### Primary: Percentage of participants with CDI recurrence

End point title	Percentage of participants with CDI recurrence
End point description:	
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic <i>C. difficile</i> following clinical cure of the initial CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic <i>C. difficile</i> ; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.	
End point type	Primary
End point timeframe:	
Up to 12 weeks	

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	232	386	383	395
Units: Percentage of participants				
number (not applicable)	25.9	17.4	15.9	27.6

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC

Number of subjects included in analysis	627
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3182 [1]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.6
upper limit	5.5

Notes:

[1] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Adjusted Difference: MK-6072 + SOC - Placebo Comparator + SOC

Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	781
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003 [2]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.9
upper limit	-4.3

Notes:

[2] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Adjusted Difference: MK-3415A + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [3]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-11.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.4
upper limit	-5.9

Notes:

[3] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description: Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC	
Comparison groups	MK-3415 + SOC v MK-3415A + SOC
Number of subjects included in analysis	615
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 [4]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-9.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.9
upper limit	-3.4

Notes:

[4] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description: Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC	
Comparison groups	MK-6072+ SOC v MK-3415A + SOC
Number of subjects included in analysis	769
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2997 [5]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.7
upper limit	3.9

Notes:

[5] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

### Primary: Percentage of participants with one or more Adverse Events (AEs) during 4 weeks following infusion

End point title	Percentage of participants with one or more Adverse Events (AEs) during 4 weeks following infusion
-----------------	--

End point description:

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency

and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The population analyzed consisted of all randomized participants who received infusion of study medication.

End point type	Primary
End point timeframe:	
Up to 28 days	

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	67.2	65.4	59.7	62

### Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.185
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	12.8

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.323
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	3.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	10.1

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.507
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.1
upper limit	4.5

**Primary: Percentage of participants with any drug-related AE during 4 weeks following infusion**

End point title	Percentage of participants with any drug-related AE during 4 weeks following infusion
End point description:	
<p>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug. The population analyzed consisted of all randomized participants who received infusion of study medication.</p>	
End point type	Primary
End point timeframe:	
Up to 28 days	

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	7.2	8.2	6.2	5

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.246
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	6.7

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.069
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	6.8

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.464
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	4.6

### Primary: Percentage of participants with any serious adverse events (SAEs) during 4 weeks following infusion

End point title	Percentage of participants with any serious adverse events (SAEs) during 4 weeks following infusion
-----------------	---

End point description:

A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. The population analyzed consisted of all randomized participants who received infusion of study medication

End point type	Primary
----------------	---------

End point timeframe:

Up to 28 days

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	27.7	21.5	14.7	20

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
----------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
-------------------	--

Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.027
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	7.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	14.7

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.594
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	7.2

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.051
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	-5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.6
upper limit	0

**Primary: Percentage of participants with any serious drug-related AEs (SAEs) during 4 weeks following infusion**

End point title	Percentage of participants with any serious drug-related AEs (SAEs) during 4 weeks following infusion
-----------------	---

End point description:

A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was an SAE determined by the investigator to be related to the drug. The population analyzed consisted of all randomized participants who received infusion of study medication

End point type	Primary
----------------	---------

End point timeframe:

Up to 28 days

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	1.3	1	0.5	0.3

**Statistical analyses**

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.115
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	3.5

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC

Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.17
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	2.4

**Statistical analysis title** Comparison of Treatment Groups

Statistical analysis description:

Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.544
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	1.6

**Primary: Percentage of participants who discontinued study medication due to an AE during 4 weeks following infusion**

End point title Percentage of participants who discontinued study medication due to an AE during 4 weeks following infusion

End point description:

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The population analyzed consisted of all randomized participants who received infusion of study medication.

End point type Primary

End point timeframe:

Up to 28 days

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	0.4	0.3	0	0

### Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.192
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	2.4

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.311
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	0.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	1.4

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.999
Method	Miettinen and Nurminen
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	1

### Secondary: Percentage of participants with infusion-specific AEs

End point title	Percentage of participants with infusion-specific AEs
End point description:	
Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension. The population analyzed consisted of all randomized participants who received infusion of study medication.	
End point type	Secondary
End point timeframe:	
Up to 24 hours	

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	390	387	400
Units: Percentage of participants				
number (not applicable)	11.1	11.8	8.8	7.5

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	8.7

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	790
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	4.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	8.5

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC

Number of subjects included in analysis	787
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	5.2

### Secondary: Percentage of participants with Global Cure

End point title	Percentage of participants with Global Cure
End point description:	
Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received $\leq$ 14 day regimen of SOC therapy and have no diarrhea ( $\leq$ 2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.	
End point type	Secondary
End point timeframe:	
Up to 12 weeks	

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	232	386	383	395
Units: Percentage of participants				
number (not applicable)	47	60.1	58.7	55.2

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	627
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9775 <sup>[6]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-8.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.3
upper limit	-0.2

Notes:

[6] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	781
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0861 [7]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	4.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	11.7

Notes:

[7] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	778
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1646 [8]
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	10.4

Notes:

[8] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC	
Comparison groups	MK-3415 + SOC v MK-3415A + SOC

Number of subjects included in analysis	615
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0025 <sup>[9]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.5
upper limit	19.7

Notes:

[9] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC	
Comparison groups	MK-6072+ SOC v MK-3415A + SOC
Number of subjects included in analysis	769
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6532 <sup>[10]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	5.5

Notes:

[10] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

### **Secondary: Percentage of participants with CDI recurrence in those with clinical cure of the initial CDI episode**

End point title	Percentage of participants with CDI recurrence in those with clinical cure of the initial CDI episode
End point description:	
<p>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic <i>C. difficile</i> following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received <math>\leq 14</math> day regimen of SOC therapy and have no diarrhea (<math>\leq 2</math> loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic <i>C. difficile</i>; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</p>	
End point type	Secondary
End point timeframe:	
Up to 12 weeks	

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	169	299	286	327
Units: Percentage of participants				
number (not applicable)	35.5	22.4	21.3	33.3

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	496
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6505 <sup>[11]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.9
upper limit	10.7

Notes:

[11] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Adjusted Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	626
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 <sup>[12]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-10.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.7
upper limit	-3.8

Notes:

[12] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Adjusted Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	613
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006 <sup>[13]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.6
upper limit	-4.7

Notes:

[13] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC	
Comparison groups	MK-3415 + SOC v MK-3415A + SOC
Number of subjects included in analysis	455
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007 <sup>[14]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-13.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.5
upper limit	-5.2

Notes:

[14] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC	
Comparison groups	MK-6072+ SOC v MK-3415A + SOC

Number of subjects included in analysis	585
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3906 <sup>[15]</sup>
Method	Miettinen and Nurminen
Parameter estimate	Adjusted Difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	5.8

Notes:

[15] - One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).

### Secondary: Percentage of participants $\geq$ 65 years of age at study entry with CDI recurrence

End point title	Percentage of participants $\geq$ 65 years of age at study entry with CDI recurrence
-----------------	--

End point description:

CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic *C. difficile* following clinical cure of the initial CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic *C. difficile*; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 weeks

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	122	185	200	199
Units: Percentage of participants				
number (not applicable)	26.2	15.1	17	33.2

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
----------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
-------------------	--

Number of subjects included in analysis	321
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.8
upper limit	3.5

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	384
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.3
upper limit	-9.6

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	399
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-16.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.5
upper limit	-7.7

<b>Secondary: Percentage of participants with a history of CDI in the 6 months prior to enrollment with CDI recurrence</b>	
End point title	Percentage of participants with a history of CDI in the 6

## End point description:

CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic *C. difficile* following clinical cure of the initial CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic *C. difficile*; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 weeks

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	69	103	96	109
Units: Percentage of participants				
number (not applicable)	33.3	26.2	25	39.4

**Statistical analyses**

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC

Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
-------------------	--

Number of subjects included in analysis	178
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority
---------------	-------------

Parameter estimate	Percentage Difference
--------------------	-----------------------

Point estimate	-6.1
----------------	------

Confidence interval

level	95 %
-------	------

sides	2-sided
-------	---------

lower limit	-20.1
-------------	-------

upper limit	8.6
-------------	-----

<b>Statistical analysis title</b>	Comparison of Treatment Groups
-----------------------------------	--------------------------------

Statistical analysis description:

Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC

Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
-------------------	---

Number of subjects included in analysis	212
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-13.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.5
upper limit	-0.5

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-14.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.8
upper limit	-1.6

<b>Secondary: Percentage of participants with clinically severe CDI at study entry with CDI recurrence</b>	
End point title	Percentage of participants with clinically severe CDI at study entry with CDI recurrence
End point description:	
<p>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic <i>C. difficile</i> following clinical cure of the initial CDI episode. With clinically severe CDI is defined as a Zar Score <math>\geq 2</math>. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic <i>C. difficile</i>; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</p>	
End point type	Secondary
End point timeframe:	
Up to 12 weeks	

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	67	62	60
Units: Percentage of participants				
number (not applicable)	25.8	10.4	12.9	25

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.9
upper limit	21

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	127
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-14.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.3
upper limit	-1.4

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC

Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-12.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.2
upper limit	1.9

### Secondary: Percentage of participants with the B1/NAP1/027 strain of C. difficile at study entry with CDI recurrence

End point title	Percentage of participants with the B1/NAP1/027 strain of C. difficile at study entry with CDI recurrence
End point description:	
<p>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</p>	
End point type	Secondary
End point timeframe:	
Up to 12 weeks	

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	46	37	36
Units: Percentage of participants				
number (not applicable)	33.3	26.1	10.8	36.1

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-10

Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.1
upper limit	10

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-25.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.7
upper limit	-6.1

**Secondary: Percentage of participants infected with an epidemic strain of C. difficile (ribotypes 027, 014, 002, 001, 106, and 020) at study entry with CDI recurrence**

End point title	Percentage of participants infected with an epidemic strain of C. difficile (ribotypes 027, 014, 002, 001, 106, and 020) at study entry with CDI recurrence
-----------------	---

End point description:

CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 weeks

<b>End point values</b>	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	57	108	106	106
Units: Percentage of participants				
number (not applicable)	24.6	23.1	19.8	35.8

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	163
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-11.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.9
upper limit	3.9

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-12.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.7
upper limit	-0.5

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description: Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC

Number of subjects included in analysis	212
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.8
upper limit	-4

### Secondary: Percentage of participants with compromised immunity at study entry with CDI recurrence

End point title	Percentage of participants with compromised immunity at study entry with CDI recurrence
End point description:	
<p>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions. The population analyzed consisted of participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</p>	
End point type	Secondary
End point timeframe:	
Up to 12 weeks	

End point values	MK-3415 + SOC	MK-6072+ SOC	MK-3415A + SOC	Placebo Comparator + SOC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	55	87	78	92
Units: Percentage of participants				
number (not applicable)	18.2	17.2	11.5	28.3

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415 + SOC v Placebo Comparator + SOC

Number of subjects included in analysis	147
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.2
upper limit	4.6

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-6072 + SOC - Placebo Comparator + SOC	
Comparison groups	MK-6072+ SOC v Placebo Comparator + SOC
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.2
upper limit	1.4

<b>Statistical analysis title</b>	Comparison of Treatment Groups
Statistical analysis description:	
Percentage Difference: MK-3415A + SOC - Placebo Comparator + SOC	
Comparison groups	MK-3415A + SOC v Placebo Comparator + SOC
Number of subjects included in analysis	170
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Percentage Difference
Point estimate	-16.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.4
upper limit	-4.7

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 90 days

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	MK-3415
-----------------------	---------

Reporting group description: -

Reporting group title	MK-3415A
-----------------------	----------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	MK-6072
-----------------------	---------

Reporting group description: -

<b>Serious adverse events</b>	MK-3415	MK-3415A	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	104 / 235 (44.26%)	94 / 387 (24.29%)	126 / 400 (31.50%)
number of deaths (all causes)	27	20	26
number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Acute myeloid leukaemia recurrent			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bladder transitional cell carcinoma			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Breast cancer</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Breast cancer metastatic</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Burkitt's lymphoma</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Colon cancer metastatic</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Gastric cancer</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Hypergammaglobulinaemia benign monoclonal</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lung neoplasm malignant</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Malignant melanoma</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Malignant melanoma in situ</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Malignant neoplasm progression</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Metastases to spine</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Myelodysplastic syndrome</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ovarian cancer metastatic</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancreatic carcinoma</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Squamous cell carcinoma</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
Deep vein thrombosis			

subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haematoma</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypertension</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypertensive crisis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypotension</b>			
subjects affected / exposed	2 / 235 (0.85%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypovolaemic shock</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Peripheral arterial occlusive disease</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Peripheral artery stenosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Peripheral artery thrombosis</b>			

subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
General physical health deterioration			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hernia obstructive			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Multi-organ failure</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
<b>Non-cardiac chest pain</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Peripheral swelling</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyrexia</b>			
subjects affected / exposed	2 / 235 (0.85%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sudden cardiac death</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Sudden death</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Immune system disorders</b>			
Acute graft versus host disease			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute graft versus host disease in intestine			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Graft versus host disease in gastrointestinal tract			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart transplant rejection			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Asthma			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Atelectasis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 235 (0.85%)	2 / 387 (0.52%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Chronic respiratory failure			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cough			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal stenosis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	3 / 400 (0.75%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Pneumonia aspiration			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumothorax			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary cavitation</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary embolism</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary oedema</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Respiratory arrest</b>			
subjects affected / exposed	0 / 235 (0.00%)	2 / 387 (0.52%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
<b>Respiratory disorder</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory failure</b>			
subjects affected / exposed	2 / 235 (0.85%)	1 / 387 (0.26%)	4 / 400 (1.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 2
<b>Sputum increased</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Psychiatric disorders</b>			
Affective disorder			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aggression			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcoholism			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug dependence			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychogenic seizure			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart rate increased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Arteriovenous fistula thrombosis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cervical vertebral fracture			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 235 (0.43%)	3 / 387 (0.78%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gun shot wound			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal anastomosis complication			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perinephric collection			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural vomiting			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Radiation oesophagitis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Rib fracture</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>Acute myocardial infarction</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
<b>Angina pectoris</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Angina unstable</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Atrial fibrillation</b>			
subjects affected / exposed	2 / 235 (0.85%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Atrial flutter</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Atrial tachycardia</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bradycardia</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bundle branch block left</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac arrest</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Cardiac disorder</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac failure</b>			
subjects affected / exposed	3 / 235 (1.28%)	1 / 387 (0.26%)	4 / 400 (1.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
<b>Cardiac failure acute</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac failure chronic</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac failure congestive</b>			

subjects affected / exposed	2 / 235 (0.85%)	3 / 387 (0.78%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardio-respiratory arrest</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiopulmonary failure</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
<b>Hypertensive heart disease</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intrapericardial thrombosis</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Myocardial infarction</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Palpitations</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sinus arrhythmia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tachycardia</b>			

subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachyarrhythmia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebrovascular accident			
subjects affected / exposed	3 / 235 (1.28%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Convulsion			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			

subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disturbance in attention			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			

subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Subarachnoid haemorrhage</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Syncope</b>			
subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Transient ischaemic attack</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	2 / 235 (0.85%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Disseminated intravascular coagulation</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	1 / 235 (0.43%)	2 / 387 (0.52%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Iron deficiency anaemia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Leukocytosis</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ear and labyrinth disorders</b>			
<b>Hearing impaired</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eye disorders</b>			
<b>Diplopia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Abdominal discomfort</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Abdominal distension</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal hernia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	4 / 235 (1.70%)	4 / 387 (1.03%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute abdomen			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	3 / 235 (1.28%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	6 / 235 (2.55%)	6 / 387 (1.55%)	6 / 400 (1.50%)
occurrences causally related to treatment / all	0 / 6	0 / 8	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perforation			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiplonic appendagitis			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecal incontinence			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis alcoholic			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal haemorrhage</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
<b>Gastrointestinal inflammation</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haematochezia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hernial eventration</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ileus</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Incarcerated umbilical hernia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Inflammatory bowel disease</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intestinal dilatation</b>			

subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Intestinal obstruction</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Large intestine perforation</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Melaena</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nausea</b>			
subjects affected / exposed	3 / 235 (1.28%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Oesophageal stenosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancreatitis</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Pancreatitis acute</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancreatitis necrotising</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 235 (0.00%)	2 / 387 (0.52%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 235 (0.00%)	3 / 387 (0.78%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholecystitis acute</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholelithiasis</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cirrhosis alcoholic</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatic cirrhosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Hepatorenal syndrome</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Portal vein thrombosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Ecchymosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eczema</b>			

subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Rash</b>			
subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin ulcer</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>Bladder dilatation</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haematuria</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nephritis autoimmune</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal failure acute</b>			
subjects affected / exposed	3 / 235 (1.28%)	3 / 387 (0.78%)	6 / 400 (1.50%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
<b>Renal failure chronic</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal impairment</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Compartment syndrome			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Connective tissue disorder			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal disorder			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Abdominal abscess			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 235 (0.43%)	3 / 387 (0.78%)	3 / 400 (0.75%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Biliary tract infection			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bronchitis viral			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			

subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bursitis infective</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Campylobacter gastroenteritis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Candida infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cellulitis</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	3 / 400 (0.75%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Clostridium difficile infection</b>			
subjects affected / exposed	26 / 235 (11.06%)	18 / 387 (4.65%)	26 / 400 (6.50%)
occurrences causally related to treatment / all	0 / 28	0 / 21	0 / 32
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Clostridium difficile sepsis</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Cystitis</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Device related infection</b>			

subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis viral			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gas gangrene			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 235 (0.00%)	3 / 387 (0.78%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis viral</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Graft infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Histoplasmosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypopyon</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infected lymphocele</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Kidney infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lobar pneumonia</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Localised infection</b>			

subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	7 / 235 (2.98%)	5 / 387 (1.29%)	11 / 400 (2.75%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 4
Pneumonia bacterial			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			

subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 235 (0.00%)	2 / 387 (0.52%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoas abscess			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonellosis			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	9 / 235 (3.83%)	3 / 387 (0.78%)	11 / 400 (2.75%)
occurrences causally related to treatment / all	0 / 9	1 / 3	0 / 11
deaths causally related to treatment / all	0 / 7	1 / 1	0 / 3
<b>Septic shock</b>			
subjects affected / exposed	3 / 235 (1.28%)	4 / 387 (1.03%)	4 / 400 (1.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 1	0 / 4
<b>Soft tissue infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Systemic candida</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Systemic mycosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tracheitis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tracheobronchitis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urinary tract infection</b>			

subjects affected / exposed	6 / 235 (2.55%)	4 / 387 (1.03%)	5 / 400 (1.25%)
occurrences causally related to treatment / all	0 / 7	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Urosepsis</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	2 / 400 (0.50%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Wound infection</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Zygomycosis</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>Dehydration</b>			
subjects affected / exposed	1 / 235 (0.43%)	3 / 387 (0.78%)	5 / 400 (1.25%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
<b>Electrolyte imbalance</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Failure to thrive</b>			
subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	1 / 400 (0.25%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Fluid overload</b>			
subjects affected / exposed	2 / 235 (0.85%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gout</b>			

subjects affected / exposed	1 / 235 (0.43%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperammonaemia</b>			
subjects affected / exposed	1 / 235 (0.43%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperglycaemia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperglycaemic hyperosmolar nonketotic syndrome</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperkalaemia</b>			
subjects affected / exposed	0 / 235 (0.00%)	0 / 387 (0.00%)	3 / 400 (0.75%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypoglycaemia</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 235 (0.00%)	1 / 387 (0.26%)	0 / 400 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	MK-6072		
Total subjects affected by serious adverse events			
subjects affected / exposed	120 / 390 (30.77%)		
number of deaths (all causes)	31		
number of deaths resulting from adverse events	1		

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myeloid leukaemia recurrent			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder transitional cell carcinoma			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Breast cancer			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Breast cancer metastatic			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Burkitt's lymphoma			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer metastatic			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Gastric cancer				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypergammaglobulinaemia benign monoclonal				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung neoplasm malignant				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	1 / 390 (0.26%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Malignant melanoma in situ				
subjects affected / exposed	1 / 390 (0.26%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm progression				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to spine				
subjects affected / exposed	1 / 390 (0.26%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Myelodysplastic syndrome				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian cancer metastatic				

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancreatic carcinoma</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Squamous cell carcinoma</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vascular disorders</b>			
<b>Deep vein thrombosis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Haematoma</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypertension</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypertensive crisis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hypotension</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypovolaemic shock</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery stenosis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery thrombosis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Asthenia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Death			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General physical health deterioration			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hernia obstructive			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malaise			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multi-organ failure			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Non-cardiac chest pain			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peripheral swelling			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sudden cardiac death			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Sudden death</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Immune system disorders</b>			
<b>Acute graft versus host disease</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Acute graft versus host disease in intestine</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Graft versus host disease</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Graft versus host disease in gastrointestinal tract</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Heart transplant rejection</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspiration			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atelectasis			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Chronic respiratory failure			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cough			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pharyngeal stenosis				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	1 / 390 (0.26%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pneumonia aspiration				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	2 / 390 (0.51%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pulmonary cavitation				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary oedema				
subjects affected / exposed	1 / 390 (0.26%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory arrest				
subjects affected / exposed	0 / 390 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory disorder				

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Respiratory failure</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
<b>Sputum increased</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Psychiatric disorders</b>			
<b>Affective disorder</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Aggression</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Alcoholism</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Confusional state</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Depression</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Drug dependence</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Mental status changes</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Psychogenic seizure</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Suicide attempt</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Investigations</b>			
<b>Alanine aminotransferase increased</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Blood alkaline phosphatase increased</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Blood bilirubin increased</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Haemoglobin decreased</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Heart rate increased</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Platelet count decreased			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Arteriovenous fistula thrombosis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical vertebral fracture			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Contusion			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gun shot wound			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Intestinal anastomosis complication			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perinephric collection			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post-traumatic pain			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural vomiting			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Radiation oesophagitis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Angina unstable			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Atrial fibrillation</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Atrial flutter</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Atrial tachycardia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Bradycardia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Bundle branch block left</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac arrest</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Cardiac disorder</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac failure</b>			

subjects affected / exposed	4 / 390 (1.03%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Cardiac failure acute			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure chronic			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiopulmonary failure			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hypertensive heart disease			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Intrapericardial thrombosis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Palpitations</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Sinus arrhythmia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Tachycardia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Ventricular tachyarrhythmia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Ventricular tachycardia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
<b>Aphasia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cerebral haemorrhage</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
<b>Cerebral infarction</b>			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cerebrovascular accident</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
<b>Convulsion</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Depressed level of consciousness</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Disturbance in attention</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Encephalopathy</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Epilepsy</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Headache</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hepatic encephalopathy</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Metabolic encephalopathy</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Partial seizures</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Presyncope</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Subarachnoid haemorrhage</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Syncope</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Transient ischaemic attack</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Disseminated intravascular coagulation</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Febrile neutropenia</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Iron deficiency anaemia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Leukocytosis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Neutropenia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Thrombocytopenia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Ear and labyrinth disorders</b>			
Hearing impaired			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Eye disorders</b>			

Diplopia			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal distension			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	3 / 390 (0.77%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Abdominal pain lower			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute abdomen			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Ascites			

subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Colitis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Colitis ulcerative</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Constipation</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Crohn's disease</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Diarrhoea</b>			
subjects affected / exposed	9 / 390 (2.31%)		
occurrences causally related to treatment / all	1 / 10		
deaths causally related to treatment / all	0 / 0		
<b>Diarrhoea haemorrhagic</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Diverticular perforation</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Diverticulum</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epiploic appendagitis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecal incontinence			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis alcoholic			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal inflammation			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematochezia			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hernial eventration			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inflammatory bowel disease			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal dilatation			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Large intestine perforation			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal stenosis			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancreatitis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancreatitis acute</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancreatitis necrotising</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Proctalgia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Rectal haemorrhage</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Small intestinal obstruction</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Umbilical hernia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Upper gastrointestinal haemorrhage</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cirrhosis alcoholic			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cirrhosis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatorenal syndrome			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Portal vein thrombosis			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Skin and subcutaneous tissue disorders</b>			
<b>Ecchymosis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Eczema</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Rash</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Skin ulcer</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Renal and urinary disorders</b>			
<b>Bladder dilatation</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Haematuria</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Nephritis autoimmune</b>			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure acute			
subjects affected / exposed	5 / 390 (1.28%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 2		
Renal failure chronic			
subjects affected / exposed	3 / 390 (0.77%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Renal impairment			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Compartment syndrome			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Connective tissue disorder			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flank pain			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemarthrosis			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Rhabdomyolysis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Spinal disorder</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Infections and infestations</b>			
<b>Abdominal abscess</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Abdominal infection</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Abscess limb</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Arthritis bacterial</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Bacteraemia</b>			
subjects affected / exposed	3 / 390 (0.77%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Biliary tract infection</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Bronchitis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Bronchitis viral</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Bronchopneumonia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Bursitis infective</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Campylobacter gastroenteritis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Candida infection</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cellulitis</b>			
subjects affected / exposed	3 / 390 (0.77%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>Clostridium difficile infection</b>			

subjects affected / exposed	10 / 390 (2.56%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 0		
<b>Clostridium difficile sepsis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cystitis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Device related infection</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Device related sepsis</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Diverticulitis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Empyema</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Encephalitis viral</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Erysipelas</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gangrene</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Gas gangrene</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gastroenteritis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Gastroenteritis viral</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Graft infection</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Histoplasmosis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hypopyon</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Infected lymphocele</b>			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Kidney infection</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Lobar pneumonia</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Localised infection</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Lower respiratory tract infection</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Mediastinitis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Osteomyelitis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Peritonitis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Pneumonia</b>			

subjects affected / exposed	7 / 390 (1.79%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 2		
Pneumonia bacterial			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia haemophilus			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural infection			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative wound infection			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pseudomembranous colitis			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psoas abscess			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Rhinovirus infection</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Salmonellosis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Sepsis</b>			
subjects affected / exposed	7 / 390 (1.79%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 3		
<b>Septic shock</b>			
subjects affected / exposed	3 / 390 (0.77%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 3		
<b>Soft tissue infection</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Systemic candida</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Systemic mycosis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Tracheitis</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Tracheobronchitis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Urinary tract infection</b>			
subjects affected / exposed	6 / 390 (1.54%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
<b>Urosepsis</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Wound infection</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Zygomycosis</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Metabolism and nutrition disorders</b>			
<b>Dehydration</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Electrolyte imbalance</b>			

subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Failure to thrive</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Fluid overload</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Gout</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hyperammonaemia</b>			
subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hyperglycaemia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hyperglycaemic hyperosmolar nonketotic syndrome</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hyperkalaemia</b>			
subjects affected / exposed	2 / 390 (0.51%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Hypoglycaemia</b>			

subjects affected / exposed	0 / 390 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypokalaemia</b>			
subjects affected / exposed	1 / 390 (0.26%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	MK-3415	MK-3415A	Placebo
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	84 / 235 (35.74%)	110 / 387 (28.42%)	103 / 400 (25.75%)
<b>Nervous system disorders</b>			
Headache			
subjects affected / exposed	15 / 235 (6.38%)	22 / 387 (5.68%)	14 / 400 (3.50%)
occurrences (all)	19	23	18
<b>General disorders and administration site conditions</b>			
Fatigue			
subjects affected / exposed	12 / 235 (5.11%)	14 / 387 (3.62%)	5 / 400 (1.25%)
occurrences (all)	13	15	5
Pyrexia			
subjects affected / exposed	14 / 235 (5.96%)	13 / 387 (3.36%)	15 / 400 (3.75%)
occurrences (all)	18	16	16
<b>Gastrointestinal disorders</b>			
Abdominal pain			
subjects affected / exposed	14 / 235 (5.96%)	20 / 387 (5.17%)	24 / 400 (6.00%)
occurrences (all)	15	21	28
Diarrhoea			
subjects affected / exposed	18 / 235 (7.66%)	33 / 387 (8.53%)	27 / 400 (6.75%)
occurrences (all)	23	38	42
Nausea			
subjects affected / exposed	30 / 235 (12.77%)	33 / 387 (8.53%)	30 / 400 (7.50%)
occurrences (all)	33	40	35
Vomiting			

subjects affected / exposed occurrences (all)	11 / 235 (4.68%) 13	15 / 387 (3.88%) 18	16 / 400 (4.00%) 16
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	15 / 235 (6.38%) 15	15 / 387 (3.88%) 15	20 / 400 (5.00%) 21

<b>Non-serious adverse events</b>	MK-6072		
Total subjects affected by non-serious adverse events subjects affected / exposed	116 / 390 (29.74%)		
Nervous system disorders Headache subjects affected / exposed occurrences (all)	20 / 390 (5.13%) 23		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)	7 / 390 (1.79%) 7  23 / 390 (5.90%) 26		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Vomiting subjects affected / exposed occurrences (all)	25 / 390 (6.41%) 32  25 / 390 (6.41%) 33  32 / 390 (8.21%) 38  23 / 390 (5.90%) 29		
Infections and infestations Urinary tract infection			

subjects affected / exposed	18 / 390 (4.62%)		
occurrences (all)	18		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 November 2010	Amendment No. 01 was finalized and approved before any participants were enrolled into the study. Major changes included: updates to the statistical analysis plan; modifications to the study procedures; changes to criteria for standard of care antibiotic switching; and changes to the criteria for when to conduct an unscheduled visit.
05 July 2011	Amendment No. 02 was finalized and approved before any participants were enrolled into the study. Major changes included: addition of fidaxomicin as an allowed standard of care antibiotic; revised eligibility criteria to (1) allow initiation of standard of care therapy within a few hours after the study medication infusion, (2) exclude participants with a condition such that they routinely pass loose stool, (3) exclude participants for whom treatment with standard of care therapy was planned for longer than 14 days; removed collection of several biological samples which had been intended for exploratory analyses; reduced study medication infusion duration from 2 hours to 1 hour; updated the statistical analysis plan to address regulatory agency advice.
20 May 2013	Amendment No.03 was implemented after enrollment of subjects had commenced and before database lock and unblinding. Major changes included: increased infusion set filter pore size to 5 micron or smaller from 0.2 microns or smaller; removed the 9-month extended follow-up portion of the study (no participants had been enrolled in the extension prior to this amendment); updated eligibility criteria to exclude participants who had received an experimental C. difficile vaccine or other experimental monoclonal antibody against C. difficile toxin A or B, or participants who planned to receive during the follow-up period fecal transplantation therapy or any other therapies that had been demonstrated to decrease CDI recurrence; modified the definition of the clinical cure endpoint with regard to the duration of standard of care medication: a 14 day regimen was defined as treatment spanning no more than 16 calendar days.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported